Live Chat
Today's Hours: 8:00am - 8:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    Dimos D. Mitsikostas, Koen Paemeleire editors.
    Contents:
    1. Headache classification
    2. Epidemiology of headache disorders
    3. General principles of pharmacotherapy for headache disorders.- 4. Placebo and nocebo effects
    5. Review of existing guidelines
    6. Acute migraine treatment
    7. Preventive (episodic) migraine treatment
    8. Drug treatment for chronic migraine
    9. Drug treatment for episodic and chronic tension-type headache (TTH)
    10. Cluster headache: acute and transitional treatment
    11. Cluster headache: preventive treatment
    12. Pharmacotherapy for other primary headache disorders
    13. Pharmacotherapy for primary headache disorders in children
    14. Pharmacological strategies in the prevention of migraine in children
    15. Pharmacotherapy for primary headache disorders during pregnancy and lactation
    16. Pharmacotherapy for primary headache disorders in the elderly
    17. Acute and chronic posttraumatic headache
    18. Headache attributed to low and increased CSF pressure
    19. Medication-overuse headache
    20. Painful cranial neuropathies
    21. Dental and Musculoskeletal Pain
    22. Post-traumatic neuropathies and Burning mouth syndrome.
    Digital Access Springer 2016
  • Article
    Onodera C, Hayashi T, Makita I, Hashi T, Takeda K, Ozeki F, Shimazu H.
    J Toxicol Sci. 1979 Aug;4(3):229-53.
    Male and female dogs, aged 17--21 months, were administered orall M 73101 (0, 60, 120 and 240 mg/kg/day), a new analgesic and antiinflammatory drug, for 27 weeks, and following recovery test was carried out for 5 weeks. Dead animals were not found throughout the experimental period. Body weight gain, and food and water consumption were not affected due to M 73101 administration. Except for a slight increase of vomitting in the highest dose, there were no abnormal symptoms. Biochemical examination showed the slight increase in serum alkaline phosphatase activity and free cholesterol level. Pathological examination revealed a dose-dependent increase of liver weight and hypertrophy of hepatocytes due to proliferation of smooth endoplasmic reticulum. In addition, mitochondria became irregularly large in the highest dose. There were no abnormal findings in the gastro-intestinal tracts except for an erosion of gastric mucosa, which was noted in a female dog treated 240 mg/kg/day of M 73101. From these results, it was suggested that the maximum non-toxic dose was 60 mg/kg/day or less, and the greatest safety dose was 120 mg/kg/day in beagle dogs.
    Digital Access Access Options